Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

Laura Leroy; Benjamin Bonhomme; Sylvestre Le Moulec; Isabelle Soubeyran; Antoine Italiano; Yann Godbert

首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

【24h】

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

机译：在先前用Crizotinib治疗的内塑性淋巴瘤激酶重新排列的共塑性淋巴瘤激酶重新排列的肾盂芳基甲状腺癌的显着反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Thyroid: official journal of the American Thyroid Association》 |2020年第2期|共2页
作者
Laura Leroy; Benjamin Bonhomme; Sylvestre Le Moulec; Isabelle Soubeyran; Antoine Italiano; Yann Godbert;
展开▼
作者单位

Bergonie Institute;

Bergonie Institute;

Bergonie Institute;

Bergonie Institute;

Bergonie Institute;

Bergonie Institute;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib [J] . Laura Leroy, Benjamin Bonhomme, Sylvestre Le Moulec, Thyroid: official journal of the American Thyroid Association . 2020,第2期

机译：在先前用Crizotinib治疗的内塑性淋巴瘤激酶重新排列的共塑性淋巴瘤激酶重新排列的肾盂芳基甲状腺癌的显着反应
2. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset [J] . ToyoakiHida, MiyakoSatouchi, KazuhikoNakagawa, Japanese journal of clinical oncology. . 2017,第7期

机译：Ceritinib在先进，蠕动肝癌治疗，内抑制淋巴瘤激酶重新排列的NSCLC：日本子集
3. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer [J] . Reckamp Karen, Lin Huamao M., Huang Joice, Current medical research and opinion . 2019,第4期

机译：Brigatinib对Creizotinib-Remplactory Anploplastic淋巴瘤激酶阳性非小细胞肺癌患者的比较疗效
4. Functional characterization of ubiquitination profile changes induced by oncogenic protein NPM-ALK in ALK~(+) anaplastic large cell lymphoma cells [C] . Fang Wu, Peng Wang, Raymond Lai, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：致癌蛋白NPM-ALK诱导ubiquitination曲线变化的功能表征Ala1（+）促进大细胞淋巴瘤细胞
5. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013

机译：了解JunB转录因子在间变性淋巴瘤激酶阳性，间变性大细胞淋巴瘤中的功能。
6. Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib [O] . Liping Lin, Fuxi Huang, Fang Chen, 2018

机译：克唑替尼成功治疗间变性淋巴瘤激酶（ALK）重排的肺多形性癌
7. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non–small cell lung cancer previously treated with crizotinib: Results from ASCEND-6 [O] . Yi-Long Wu, Yuankai Shi, Daniel Shao Weng Tan, 2020

机译：中医患者Ceritinib的第1/2阶段研究先前用Crizotinib治疗的非小细胞肺癌的非小细胞肺癌：Ascend-6结果

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib

著录项

相似文献

相关主题

期刊订阅